Sevostyanova V V, Antonova L V, Velikanova E A, Matveeva V G, Krivkina E O, Glushkova T V, Mironov A V, Burago A Yu, Barbarash L S
Research Institute for Complex Problems of Cardiovascular Disease, Kemerovo, Russia.
Bull Exp Biol Med. 2018 Jun;165(2):264-268. doi: 10.1007/s10517-018-4144-4. Epub 2018 Jun 20.
We have previously developed a polycaprolactone (PCL) vascular graft with incorporated vascular endothelial growth factor (VEGF). Functioning of the PCL/VEGF graft in rat circulatory system over 1, 3 and 6 months after implantation into abdominal aorta was tested. Graft patency and formation of vascular wall elements were assessed histologically and by immunofluorescence staining for von Willebrand factor, CD31, CD34, and collagens I and IV and DAPI staining. Local application of VEGF promoted endothelialization and improved patency of the graft. The wall of the PCL/VEGF graft underwent remodeling due to active cellular infiltration and the extracellular matrix deposition.
我们之前研发了一种含有血管内皮生长因子（VEGF）的聚己内酯（PCL）血管移植物。将该PCL/VEGF移植物植入大鼠腹主动脉后，对其在1个月、3个月和6个月时在大鼠循环系统中的功能进行了测试。通过组织学以及对血管性血友病因子、CD31、CD34、I型和IV型胶原蛋白进行免疫荧光染色和DAPI染色，评估移植物的通畅情况和血管壁成分的形成。VEGF的局部应用促进了内皮化并改善了移植物的通畅性。由于活跃的细胞浸润和细胞外基质沉积，PCL/VEGF移植物的血管壁发生了重塑。
